These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23269074)

  • 1. Multiple myeloma : recent progress in diagnosis and treatment.
    Chou T
    J Clin Exp Hematop; 2012; 52(3):149-59. PubMed ID: 23269074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of multiple myeloma in the newly diagnosed patient.
    Mateos MV; San Miguel JF
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):498-507. PubMed ID: 29222298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?
    Kazandjian D; Mo CC; Landgren O; Richardson PG
    Br J Haematol; 2020 Dec; 191(5):692-703. PubMed ID: 32501533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple myeloma.
    Holstein SA; Liu H; McCarthy PL
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1113-29. PubMed ID: 25459182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tandem bone marrow transplantation in multiple myeloma.
    Chng WJ
    N Engl J Med; 2004 Apr; 350(14):1466-7; author reply 1466-7. PubMed ID: 15074003
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
    Voorhees PM; Usmani SZ
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):719-28. PubMed ID: 27673290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma: future directions in autologous transplantation and novel agents.
    Hari PN; McCarthy PL
    Biol Blood Marrow Transplant; 2013 Jan; 19(1 Suppl):S20-5. PubMed ID: 23290439
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of prior induction therapy with melphalan on subsequent peripheral blood progenitor cell transplantation for myeloma.
    Kazmi MA; Ahsan G; Schey SA
    Clin Lab Haematol; 2001 Apr; 23(2):125-9. PubMed ID: 11488852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of transplant in multiple myeloma.
    Barlogie B
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):604-6. PubMed ID: 16167043
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment for patients with newly diagnosed multiple myeloma in 2015.
    Mateos MV; Ocio EM; Paiva B; Rosiñol L; Martínez-López J; Bladé J; Lahuerta JJ; García-Sanz R; San Miguel JF
    Blood Rev; 2015 Nov; 29(6):387-403. PubMed ID: 26094881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
    Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
    Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series.
    Nooka AK; Harvey RD; Langston A; Collins H; Lonial S; Kaufman JL
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e59-63. PubMed ID: 24378319
    [No Abstract]   [Full Text] [Related]  

  • 14. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
    Reichardt VL; Okada CY; Stockerl-Goldstein KE; Bogen B; Levy R
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):157-63. PubMed ID: 9310193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of multiple myeloma.
    UK myeloma forum. British Committee for Standards in Haematology
    Br J Haematol; 2001 Dec; 115(3):522-40. PubMed ID: 11736932
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma.
    Nampoothiri RV; Kasudhan KS; Patil AN; Malhotra P; Khadwal A; Prakash G; Jain A; Malhotra S; Verma Attri S; Varma N; Varma S; Lad DP
    Bone Marrow Transplant; 2019 Dec; 54(12):2088-2095. PubMed ID: 31406224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
    Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
    Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Hitz F
    Praxis (Bern 1994); 2016; 105(21):1255-1260. PubMed ID: 28573955
    [No Abstract]   [Full Text] [Related]  

  • 19. An overview of the progress in the treatment of multiple myeloma.
    Kyle RA; Rajkumar SV
    Expert Rev Hematol; 2014 Feb; 7(1):5-7. PubMed ID: 24433105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How is patient care for multiple myeloma advancing?
    Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A
    Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.